



Current Agreements

Dealdoc

Co-promotion agreement for olmesartan medoxomil

Pfizer
Daiichi Sankyo

Apr 04 2011

Co-promotion agreement for olmesartan medoxomil

Companies:	Pfizer Daiichi Sankyo
Announcement date:	Apr 04 2011
Deal value, US\$m:	n/d

- [Details](#)
- [Financials](#)
- [Termsheet](#)
- [Press Release](#)
- [Filing Data](#)
- [Contract](#)

Details

Announcement date:	Apr 04 2011
Industry sectors:	Bigpharma Pharmaceutical
Therapy areas:	Cardiovascular » Hypertension
Technology types:	Small molecules
Deal components:	Co-promotion Promotion
Stages of development:	Marketed
Geographic focus:	Asia » China

Financials

Deal value, US\$m:	n/d
--------------------	-----

Termsheet

Pfizer has agreed to co-promote a hypertension drug from Daiichi Sankyo Pharma in China.

Press Release

Pfizer has agreed to co-promote a hypertension drug from Daiichi Sankyo Pharma in China. The two companies will cooperate on selling olmesartan medoxomil, known as Benicar in the US and Olmetec in the EU and Canada. It is a member of the angiotensin II receptor antagonist class of drugs.

Filing Data

Not available.

Contract

Not available.